TITLE

The role of pulmonary pressure/cardiac index to identify pulmonary hemodynamic responders to acute oxygen breathing pulmonary hypertension COPD patients

AUTHOR(S)
Lupi-Herrera, Eulo; Sandoval, Julio; Santos, Luis Efren; Pulido, Tomas; Rosas-Peralta, Martin
PUB. DATE
July 2011
SOURCE
Archivos de Cardiología de México;jul-sep2011, Vol. 81 Issue 3, p208
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objectives: We sought to analyze exercise-derived mean pulmonary artery pressure (Mpap) - cardiac index (CI) - relationship to expand the concepts regarding its nature and to better identify pulmonary hemodynamic responders to acute oxygen breathing (AOB - 99.5%) in pul-monary hypertension (PH) - COPD patients. Methods: mPAP/CI and extrapolated pressure (Pext) to zero flow were obtained breathing room air (BRA) and under AOB - 99.5% in 40 stable COPD patients with rest and exercise PH. Hemodynamic characteristics were analyzed for the entire cohort and separate for cases those with resting < or > 30 mmHg mPAP (cohort - A and B, respectively). Results: mPAP/CI abnormal location, slope (Sp: 5.77; 95% CI: 5.02 - 6.52 mmHg/L min/m2) and Pext values (15.8 mmHg) were associated with hypoxemia/decreased mixed venous - P02 and lung mechanics abnormalities. Hemodynamic conditions that did not change for Sp (5.47; 95% CI: 3.64 - 7.3 mmHg/L min/m2, p = 0.4) and Pext (15.7 mmHg, p = 0.2) associated with a mPAP/CI significantly decrease in parallel during AOB - 99.5%. For cohort - A, an average-mPAP decline (12.3 mmHg, p <0.004) associated with a slope decrease (from 6.02; 95% CI: 4.04 - 8 to 4.3; 95% CI: 4.11 - 4.49 mmHg/L min/m2, (p <0.008), mPAP/CI - 95% CI down-ward displacement and Pext decrease (from 8.58 ± 3 to 4.7 ± 1.4 mmHg, p <0.01) in relation to BRA were observed. Forcohort-B, average-mPAP and mPAP/CI - 95% CI location did not change, Sp show a trend to decrease (p = 0.08) and Pext significantly increase (from 12 ± 2.9 to 20.6 ± 4.9 mmHg, p <0.03) in relation to BRA. Under AOB - 99.5%, significant differences for mPAP/ CI - 95% CI location, average-mPAP (A: 19.5 ± 6 vs. B: 41.2 ± 11.5 mmHg, p <0.001) and Pext (A: 4.7 ± 1.4 vs. B: 20.6 ± 4.9 mmHg, p <0.001), without Sp change between cohorts A and B were documented.
ACCESSION #
72673180

 

Related Articles

  • Effects of Different Pulmonary Vasodilators on Arterial Saturation in a Model of Pulmonary Hypertension. Becker, Eva Maria; Stasch, Johannes-Peter; Bechem, Martin; Keldenich, Jörg; Klipp, Alexandra; Schaefer, Katja; Ulbrich, Hannes-Friedrich; Truebel, Hubert // PLoS ONE;Aug2013, Vol. 8 Issue 8, p1 

    Background: Approved therapies for pulmonary arterial hypertension can induce oxygen desaturation when administered to patients with secondary forms of pulmonary hypertension (PH), probably due to an increase in ventilation/perfusion mismatch. Thus, so far these treatments have largely failed in...

  • Vasodilator-Responsive Idiopathic Pulmonary Arterial Hypertension: Evidence for a New Disease? Brittain, Evan L.; Hemnes, Anna R. // Annals of Internal Medicine;1/20/2015, Vol. 162 Issue 2, p148 

    The article presents a study on diagnosis, risk factors and treatment of patients with Idiopathic pulmonary arterial hypertension (IPAH), which is a highly morbid disease characterized by progressive obliteration of precapillary arterioles. Topics discussed include the pulmonary vascular...

  • Highly active antiretroviral therapy compared with HAART and bosentan in combination in patients with HIV-associated pulmonary hypertension. Barbaro, G.; Lucchini, A.; Pellicelli, A. M.; Grisorio, B.; Giancaspro, G.; Barbarini, G. // Heart;Aug2006, Vol. 92 Issue 8, p1164 

    The study assess the effect of combined highly active antiretroviral therapy and bosentan therapy on the exercise capacity and cardiopulmonary hemodynamics of previously untreated HIV-positive patients with pulmonary arterial hypertension. Patients treated with the combination therapy had a mean...

  • Association of HLA Class II Genes with Idiopathic Pulmonary Arterial Hypertension in Koreans. Sung-Ho Yoon; Heung-Bum Oh; Hyun-Kuk Kim; Suk-Chan Hong; Yeon-Mok Oh; Dong Soon Lee; Sang-Do Lee // Lung;May/Jun2007, Vol. 185 Issue 3, p145 

    The aim of this study was to compare the frequency of the HLA-DRB1 and HLA-DQB1 alleles in Korean patients with idiopathic pulmonary arterial hypertension (IPAH) and in normal controls and to determine any association that may exist between clinical characteristics of IPAH and specific HLA...

  • Treatment of ethanol-induced acute pulmonary hypertension and right ventricular dysfunction in pigs, by sildenafil analogue (UK343-664) or nitroglycerin. Sidi, Avner; Naik, Bhiken; Urdaneta, Felipe; Muehlschlegel, Jochen D.; Kirby, David S.; Lobato, Emilio B. // Annals of Cardiac Anaesthesia;Jul-Dec2008, Vol. 11 Issue 2, p97 

    In patients at risk for sudden ethanol (ETOH) intravascular absorption, prompt treatment of pulmonary hypertension (PHTN) will minimise the risk of cardiovascular decompensation. We investigated the haemodynamic effects of intravenous ETOH and the pulmonary vasodilatory effects of a sildenafil...

  • Long-term echocardiographic follow-up of a patient with primary pulmonary hypertension receiving iloprost inhalations. Pettersen, Eirik; Morstøl, Torstein Holm; Vegsundvåg, Johnny Aage // European Journal of Echocardiography;2005, Vol. 6 Issue 1, p67 

    Iloprost inhalation has recently emerged as an alternative therapy for severe primary pulmonary hypertension. In the studies documenting the effect of iloprost inhalation therapy, hemodynamic variables have been measured invasively. We have followed a patient with primary pulmonary hypertension...

  • Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration. Pullamsetti, Soni; Krick, Stefanie; Yilmaz, Hüseyin; Ghofrani, Hossein Ardeschir; Schudt, Christian; Weissmann, Norbert; Fuchs, Beate; Seeger, Werner; Grimminger, Friedrich; Schermuly, Ralph Theo // Respiratory Research;2005, Vol. 6, p128 

    Background: The aim of the study was to assess the chronic effects of combined phosphodiesterase 3/4 inhibitor tolafentrine, administered by inhalation, during monocrotaline-induced pulmonary arterial hypertension (PAH) in rats. Methods: CD rats were given a single subcutaneous injection of...

  • Präkapilläre pulmonale Hypertonie. Schulz, R. // Somnologie;Mar2014, Vol. 18 Issue 1, p31 

    Precapillary pulmonary hypertension (PH) is defined by hemodynamic variables (i.e., a mean pulmonary artery pressure ≥ 25 mmHg in the presence of normal pulmonary capillary wedge pressure). The relationship between PH and sleep-disordered breathing is more complex than initially thought....

  • Clinical Impact of Atrial Fibrillation in Patients with Pulmonary Hypertension. Rottlaender, Dennis; Motloch, Lukas J.; Schmidt, Daniela; Reda, Sara; Larbig, Robert; Wolny, Martin; Dumitrescu, Daniel; Rosenkranz, Stephan; Erdmann, Erland; Hoppe, Uta C. // PLoS ONE;Mar2012, Vol. 7 Issue 3, p1 

    Background: Pulmonary hypertension (PH) is associated with progressive impairment of right ventricular function, reduced exercise capacity and a poor prognosis. Little is known about the prevalence, clinical manifestation and impact of atrial fibrillation (AF) on cardiac function in PH. Methods:...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics